CytomX Therapeutics (CTMX) Total Current Liabilities (2016 - 2025)
CytomX Therapeutics (CTMX) has disclosed Total Current Liabilities for 12 consecutive years, with $41.0 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Total Current Liabilities fell 65.59% year-over-year to $41.0 million, compared with a TTM value of $41.0 million through Sep 2025, down 65.59%, and an annual FY2024 reading of $85.8 million, down 44.99% over the prior year.
- Total Current Liabilities was $41.0 million for Q3 2025 at CytomX Therapeutics, up from $39.2 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $155.9 million in Q4 2023 and bottomed at $39.2 million in Q2 2025.
- Average Total Current Liabilities over 5 years is $102.5 million, with a median of $94.6 million recorded in 2022.
- The sharpest move saw Total Current Liabilities skyrocketed 95.98% in 2022, then tumbled 72.54% in 2025.
- Year by year, Total Current Liabilities stood at $77.9 million in 2021, then surged by 95.98% to $152.6 million in 2022, then rose by 2.17% to $155.9 million in 2023, then tumbled by 44.99% to $85.8 million in 2024, then plummeted by 52.17% to $41.0 million in 2025.
- Business Quant data shows Total Current Liabilities for CTMX at $41.0 million in Q3 2025, $39.2 million in Q2 2025, and $50.2 million in Q1 2025.